CR Boya Bio-pharmaceutical, a 30.48%-owned subsidiary of CHINARES PHARMA, reported a sharp contraction in first-quarter earnings for the period ended 31 March 2026.

Revenue fell to RMB 321.13 million, a 40.1% year-on-year decline from RMB 535.88 million. Net profit slipped 78.4% to RMB 30.03 million, down from RMB 139.29 million in the same period last year.

Operating cash outflow narrowed: net cash decreased by RMB 303.00 million versus a RMB 713.11 million outflow a year earlier. Cash and cash equivalents at quarter-end stood at RMB 220.61 million, down 62.3% from RMB 585.46 million a year ago.

Total assets edged down 2.5% from year-end 2025 to RMB 8.41 billion, while total liabilities dropped 20.6% to RMB 942.80 million. Owners’ equity inched up 0.3% to RMB 7.46 billion.

The quarterly figures are unaudited and prepared under PRC GAAP; they may be subject to adjustment during the annual audit. The data cover CR Boya Bio-pharmaceutical only and do not represent the consolidated results of CHINARES PHARMA.